Renal Cell Carcinoma | Pharmacor | G7 | 2014

Renal cell carcinoma (RCC) is a disease characterized by significant unmet need and, thus, opportunity. Its incidence is increasing in the major pharmaceutical markets, and many patients with early-stage disease suffer a recurrence. Moreover, the current therapies used to treat stage IV RCC can increase progression-free survival but have limited impact on prolonging overall survival. Interviewed experts are enthusiastic about the promise of an emerging class of drugs for RCC: immune checkpoint inhibitors.

Note: In April 2015, the RCC market was updated to reflect changes in our market assumptions for sorafenib (Bayer HealthCare/Onyx Pharmaceuticals’ Nexavar).